CHRS
Coherus Oncology, Inc.Company Information
- Company Name
- Coherus Oncology, Inc.
- CIK
- CIK0001512762
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CHRS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CHRS
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2025-05-23
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 99,988
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 68,920,732
- Shares outstanding
- 154,816,912
- Ownership
- 44.52%
Earnings Market Reaction
- Filing date
- 2026-08-05
- Price on filing date
- —
- 1-month reaction
- -2.76%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 83 | 115 | 89 | 103 | 217 | 82 | 126 | 98 | 159 | 260 | 103 | 80 | ||||||
| Marketable Securities Current | 22 | 52 | 83 | 88 | 21 | - | - | - | - | - | 15 | 51 | ||||||
| Receivables Net Current | 14 | 22 | 18 | 9 | 5 | 60 | 111 | 168 | 175 | 252 | 261 | 217 | ||||||
| Inventory Net | 6 | 5 | 3 | 2 | 5 | 4 | 4 | 48 | 62 | 62 | 63 | 67 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 9 | 6 | 9 | 12 | 16 | 10 | 14 | 14 | 14 | 11 | 16 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | 72 | - | - | - | - | - | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | - | - | - | - | - | 139 | - | - | - | - | - | - | ||||||
| Assets Current | 134 | 206 | 207 | 461 | 380 | 310 | 342 | 369 | 558 | 627 | 476 | 444 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 5 | 6 | ||||||
| Inventory Noncurrent | 8 | 10 | 0 | - | - | - | 0 | 71 | 50 | 66 | 67 | 79 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 72 | - | ||||||
| Intangible Assets Net Including Goodwill | 45 | 46 | 46 | 49 | 52 | 53 | 54 | 54 | 55 | 57 | 72 | 47 | ||||||
| Other Assets Noncurrent | 3 | 4 | 4 | 4 | 5 | 6 | 6 | 7 | 8 | 9 | 10 | 8 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | 44 | - | - | - | - | - | ||||||
| Assets | 191 | 266 | 258 | 517 | 439 | 371 | 449 | 505 | 675 | 764 | 630 | 584 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 13 | 11 | 10 | 25 | 38 | 41 | 28 | 22 | 77 | 38 | 35 | 37 | ||||||
| Employee Related Liabilities Current | 10 | 15 | 15 | 13 | 11 | 20 | 18 | 16 | 14 | 23 | 22 | 18 | ||||||
| Accrued Liabilities Current | 15 | 15 | 20 | 13 | 14 | 46 | 60 | 61 | 61 | 116 | 105 | 67 | ||||||
| Loans Payable Current | - | - | - | - | - | - | - | - | - | 175 | - | - | ||||||
| Liabilities Current | 76 | 132 | 140 | 372 | 264 | 255 | 283 | 296 | 463 | 538 | 332 | 240 | ||||||
| Convertible Subordinated Debt Noncurrent | - | - | - | - | - | 229 | 228 | 228 | 228 | 227 | 227 | 227 | ||||||
| Other Liabilities Noncurrent | 18 | 17 | 18 | 18 | 17 | 31 | 29 | 29 | 28 | 3 | 13 | 4 | ||||||
| Liabilities | 130 | 187 | 197 | 429 | 320 | 555 | 581 | 593 | 759 | 845 | 823 | 717 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,503 | 1,500 | 1,444 | 1,433 | 1,430 | 1,424 | 1,419 | 1,413 | 1,406 | 1,395 | 1,386 | 1,367 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -1,442 | -1,421 | -1,383 | -1,345 | -1,310 | -1,608 | -1,551 | -1,500 | -1,490 | -1,477 | -1,580 | -1,500 | ||||||
| Stockholders Equity | 61 | 79 | 61 | 88 | 120 | -183 | -132 | -88 | -84 | -82 | -193 | -134 | ||||||
| Liabilities And Stockholders Equity | 191 | 266 | 258 | 517 | 439 | 371 | 449 | 505 | 675 | 764 | 630 | 584 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 154 | 154 | 121 | 116 | 116 | 116 | 116 | 115 | 115 | 113 | 112 | 109 | ||||||
| Shares Outstanding | 154 | 154 | 121 | 116 | 116 | 116 | 116 | 115 | 115 | 113 | 112 | 109 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCoherus Oncology, Inc. (CHRS) — SEC Financial Statements & Analysis
Coherus Oncology, Inc. (CHRS) is a biological products, (no diagnostic substances) company, incorporated in DE. Coherus Oncology, Inc. trades on Nasdaq as: CHRS. Coherus Oncology, Inc. (CHRS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05. Based on that filing, Coherus Oncology, Inc. carries a market cap of $216.74M, a P/E ratio of -1.64x, a P/B ratio of 3.56x, a P/S ratio of 4.26x, an enterprise value of $133.58M, and an EV/EBITDA multiple of -0.86x. On profitability, it posts a gross margin of 68.94%, an operating margin of -311.56%, a net margin of -259.41%, a Return on Equity (ROE) of -146.27%, and a Return on Assets (ROA) of -41.90%. Per share, it reports EPS of $-0.85, diluted EPS of $-0.85, free cash flow per share of $-1.20, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 61.00% year-over-year, net income growth of -173.51% year-over-year, and EPS growth of -155.11% year-over-year. On the balance sheet, it maintains a current ratio of 1.77x, a quick ratio of 1.63x, working capital of $58.28M, a debt-to-equity ratio of 2.14x, a debt ratio of 0.68, an interest coverage ratio of -17.47x, free cash flow of $-186.03M (TTM), and net debt of $-83.16M. Figures sourced from SEC EDGAR.
- Market Cap
- $216.74M
- P/E TTM
- -1.64x
- EPS TTM
- $-0.85
- P/B TTM
- 3.56x
- ROE TTM
- -146.27%
- ROA TTM
- -41.90%
- Debt To Equity
- 2.14x
- Free Cash Flow TTM
- $-186.03M
- Net Revenue TTM Growth 1Y
- 61.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Coherus Oncology, Inc. in?
Coherus Oncology, Inc. (CHRS) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CHRS trade on?
Coherus Oncology, Inc. (CHRS) trades on the Nasdaq.
Where is Coherus Oncology, Inc. incorporated?
Coherus Oncology, Inc. is incorporated in DE.
When was Coherus Oncology, Inc. (CHRS)'s most recent SEC filing?
Coherus Oncology, Inc. (CHRS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-05.
What is CHRS's market cap?
Coherus Oncology, Inc. (CHRS) has a market capitalization of $216.74M as of 2026-06-30.
What is CHRS's EPS (earnings per share)?
Coherus Oncology, Inc. (CHRS)'s trailing twelve month EPS is $-0.85 as of 2026-06-30.
What is CHRS's ROE (return on equity)?
Coherus Oncology, Inc. (CHRS)'s trailing twelve month Return on Equity (ROE) is -146.27% as of 2026-06-30.
What is CHRS's ROA (return on assets)?
Coherus Oncology, Inc. (CHRS)'s trailing twelve month Return on Assets (ROA) is -41.90% as of 2026-06-30.
What is CHRS's EV/EBITDA?
Coherus Oncology, Inc. (CHRS)'s trailing twelve month EV/EBITDA is -0.86x as of 2026-06-30.